ZD1839
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ZD1839, covering 2009-05-14 to 2023-11-29. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma [Phase 2]